Wednesday, June 24, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 882 of 1,261

  1. US 8394794

    Therapeutic compounds

    Regents of the University of Minnesota · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  2. US 8394357

    Optical determination of glucose utilizing boronic acid adducts

    The Regents of the University of California · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  3. US 8394365

    Multi-arm polymer prodrugs

    Nektar Therapeutics · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  4. US 8394375

    Antibodies for amyloid specific peptides

    The Regents of the University of California · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  5. US 8394380

    Compositions and methods for alzheimer's disease

    Primex Clinical Laboratories, Inc. · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  6. US 8394387

    Recombinant modified Bacillus anthracis protective antigen for use in vaccines

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  7. US 8394405

    Once daily formulations of tetracyclines

    Supernus Pharmaceuticals, Inc. · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  8. US 8394406

    Once daily formulations of tetracyclines

    Supernus Pharmaceuticals, Inc. · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  9. US 8394411

    Papillomavirus pseudoviruses for detection and therapy of tumors

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES OFFICE OF TECHNOLOGY TRANSFER, NATIONAL INSTITUTES OF HEALTH · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  10. US 8394583

    VH4 codon signature for multiple sclerosis

    The Board of Regents of the University of Texas System · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  11. US 8394764

    Griffithsin, glycosylation-resistant griffithsin, and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of use

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  12. US 8394788

    Phenylsulfoxyoxazole compound inhibitors of urea transporters

    The Regents of the University of California · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  13. US 8394803

    Gyrase inhibitors and uses thereof

    Vertex Pharmaceuticals Incorporated · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  14. US 8394951

    Protein kinase C inhibitors and uses thereof

    Rigel Pharmaceuticals, Inc. · Granted Mar 12, 2013 · Expires Mar 7, 2033

    granted

  15. US 8389502

    Stabilized steroid composition and method for its preparation

    Precision Dermatology, Inc. · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  16. US 8391959

    Composition for improving efficiency of drug delivery

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  17. US 8389736

    Compounds having activity in correcting mutant-CFTR processing and uses thereof

    The Regents of the University of California · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  18. US 8389515

    2,4-pyrimidinediamine compounds and prodrugs and their uses

    Rigel Pharmaceuticals, Inc. · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  19. US 8389731

    Chiral pyrrolidine core compounds en route to inhibitors of nitric oxide synthase

    Northwestern University · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  20. US 8389679

    Targeted antimicrobial moieties

    The Regents of the University of California · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  21. US 8389727

    Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide

    Vertex Pharmaceuticals Incorporated · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  22. US 8389759

    Oligomer-anticholinergic agent conjugates

    Nektar Therapeutics · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  23. US 8388933

    Multimeric protein toxins to target cells having multiple identifying characteristics

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

  24. US 8389478

    Methods and compositions for treating neurodegenerative disorders and Alzheimer's disease and improving normal memory

    The Regents of the University of California · Granted Mar 5, 2013 · Expires Feb 28, 2033

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.